Over 80% of pharmaceutically relevant proteins remain difficult to drug with current therapeutic modalities, leaving many diseases with no effective therapies, especially in the realm of oncology and inflammatory disorders. Biologics have difficulty entering cells and therefore cannot reach many targets while small molecules do not exhibit sufficient binding to numerous protein surfaces. Pure-DEL discovers orally available macrocycles for challenging targets using its proprietary drug discovery platform, which for the first time allows creating very large libraries (>1 billion molecules) of chemically synthesized complex macrocycles to yield orally bioavailable ligands, usable against difficult targets. Pure-DEL is a team of four scientists from ETH who co-developed Pure-DEL technology.
